Gradient Investments LLC boosted its holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 12.5% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 42,171 shares of the biotechnology company’s stock after acquiring an additional 4,702 shares during the quarter. Gradient Investments LLC’s holdings in BioMarin Pharmaceutical were worth $3,566,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Scout Investments Inc. increased its stake in BioMarin Pharmaceutical by 246.0% in the 4th quarter. Scout Investments Inc. now owns 401,147 shares of the biotechnology company’s stock valued at $33,917,000 after buying an additional 285,203 shares during the last quarter. Essex Investment Management Co. LLC increased its stake in BioMarin Pharmaceutical by 16.9% in the 3rd quarter. Essex Investment Management Co. LLC now owns 7,753 shares of the biotechnology company’s stock valued at $523,000 after buying an additional 1,119 shares during the last quarter. River & Mercantile Asset Management LLP purchased a new stake in BioMarin Pharmaceutical in the 2nd quarter valued at about $568,000. Partner Investment Management L.P. increased its stake in BioMarin Pharmaceutical by 14.6% in the 3rd quarter. Partner Investment Management L.P. now owns 29,341 shares of the biotechnology company’s stock valued at $1,978,000 after buying an additional 3,731 shares during the last quarter. Finally, Metropolitan Life Insurance Co NY increased its stake in BioMarin Pharmaceutical by 1.2% in the 3rd quarter. Metropolitan Life Insurance Co NY now owns 13,172 shares of the biotechnology company’s stock valued at $888,000 after buying an additional 158 shares during the last quarter. 95.51% of the stock is currently owned by institutional investors and hedge funds.

In related news, Director V Bryan Lawlis sold 3,750 shares of BioMarin Pharmaceutical stock in a transaction that occurred on Tuesday, December 17th. The shares were sold at an average price of $83.36, for a total value of $312,600.00. Following the completion of the transaction, the director now directly owns 27,340 shares in the company, valued at approximately $2,279,062.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP George Eric Davis sold 3,190 shares of BioMarin Pharmaceutical stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $79.66, for a total transaction of $254,115.40. Following the completion of the transaction, the executive vice president now owns 68,709 shares of the company’s stock, valued at $5,473,358.94. The disclosure for this sale can be found here. Insiders sold a total of 29,940 shares of company stock valued at $2,374,645 over the last quarter. 1.90% of the stock is owned by company insiders.

BMRN has been the subject of several analyst reports. Citigroup reiterated a “buy” rating and issued a $95.00 price objective (down previously from $120.00) on shares of BioMarin Pharmaceutical in a research note on Wednesday, October 30th. TheStreet upgraded shares of BioMarin Pharmaceutical from a “d+” rating to a “c-” rating in a research note on Thursday, December 26th. Raymond James lowered shares of BioMarin Pharmaceutical from an “outperform” rating to a “market perform” rating in a research note on Thursday, January 2nd. Bank of America restated a “buy” rating and set a $90.00 price target on shares of BioMarin Pharmaceutical in a research note on Wednesday, December 11th. Finally, Canaccord Genuity decreased their price target on shares of BioMarin Pharmaceutical from $117.00 to $108.00 and set a “buy” rating for the company in a research note on Monday, October 28th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and thirteen have assigned a buy rating to the company. BioMarin Pharmaceutical presently has a consensus rating of “Buy” and a consensus target price of $111.53.

BioMarin Pharmaceutical stock opened at $88.87 on Thursday. BioMarin Pharmaceutical Inc. has a 1-year low of $62.88 and a 1-year high of $100.13. The firm has a market capitalization of $15.99 billion, a price-to-earnings ratio of -269.30 and a beta of 1.32. The company has a current ratio of 3.77, a quick ratio of 2.53 and a debt-to-equity ratio of 0.27. The firm has a 50 day simple moving average of $83.74 and a 200 day simple moving average of $77.36.

BioMarin Pharmaceutical (NASDAQ:BMRN) last released its quarterly earnings data on Wednesday, October 23rd. The biotechnology company reported $0.31 earnings per share for the quarter, beating analysts’ consensus estimates of $0.06 by $0.25. BioMarin Pharmaceutical had a negative net margin of 2.65% and a negative return on equity of 1.35%. The business had revenue of $461.10 million during the quarter, compared to analyst estimates of $455.78 million. During the same period in the previous year, the business earned ($0.07) EPS. BioMarin Pharmaceutical’s revenue was up 17.7% compared to the same quarter last year. On average, equities research analysts forecast that BioMarin Pharmaceutical Inc. will post 0.01 EPS for the current year.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc, a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.

Recommended Story: How prevalent are 12b-1 fees?

Institutional Ownership by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.